ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter …

Abstract Background Carbapenem-resistant Acinetobacter baumannii (CRAB) has gained
global notoriety as a critically important nosocomial pathogen. It mostly affects debilitated …

Purpose Recent years have seen a change in the way that clinical trials are being
conducted. There has been a rise of designs more flexible than traditional adaptive and …

Randomized controlled trials are the gold standard to investigate efficacy and safety of new
treatments. In certain settings, however, randomizing patients to control may be difficult for …

Antimicrobial resistance is a global health threat. Among Gram-negative bacteria, resistance
to carbapenems, a class of β-lactam antibiotics, is usually a proxy for difficult-to-treat …

Background We aimed to describe the clinical characteristics and outcomes of patients
treated with meropenem-vaborbactam (MEV) for a variety of gram-negative infections …

Antimicrobial resistance (AMR) continues to pose a major global threat (1). In response, a 24
number of new antibiotics have been developed and approved for use over the last few …

Introduction: The emergence and diffusion of multidrug-resistant Gram-negative bacteria
(MDR-GNB) is an unprecedented threat, with prevalences as high as 10–50% being …

ABSTRACT Ceftolozane/tazobactam (C/T) is a novel β-lactam/β-lactamase inhibitor
combination targeting Enterobacteriaceae and Pseudomonas aeruginosa (PA). It is …

The value of model‐based translation in drug discovery and development is now effectively
being recognized in many disease areas and among various stakeholders. Such …